Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2018 | Updates from ASH in CLL therapy: big trials, big results

Peter Hillmen • 4 Dec 2018
ASH 2018
Chronic Lymphocytic Leukemia Leukemia Ibrutinib Obinutuzumab Rituximab Venetoclax
ALLIANCE A041202 ECOG-E1912 iLLUMINATE MURANO

Peter Hillmen, MBChB, FRCP, FRCPath, PhD, of the University of Leeds, Leeds, UK, shares an overview of key updates in treatment for chronic lymphocytic leukemia (CLL), including the MURANO (NCT02005471), iLLUMINATE (NCT02264574), ALLIANCE A041202 (NCT01886872), and ECOG-E1912 (NCT02048813) studies, aiming to uncover the most effective initial therapy for CLL. Speaking from the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA, Prof. Hillmen describes the superiority of frontline targeted treatments compared with chemotherapy.

More from Peter Hillmen

1:55
Key updates from the interim analysis of the FLAIR trial
Peter Hillmen • 10 Jun 2022
1:03
CLL trial updates from EHA 2022
Peter Hillmen • 10 Jun 2022
1:19
Acalabrutinib vs ibrutinib in previously untreated high-risk CLL
Peter Hillmen • 10 Jun 2022
1:40
The role of MRD in decision-making in CLL
Peter Hillmen • 10 Jun 2022

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals